✦ LIBER ✦

Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome

✍ Scribed by Peter K. Sand; Roger R. Dmochowski; Norman R. Zinner; David R. Staskin; Rodney A. Appell

Publisher: Springer
Year: 2009
Tongue: English
Weight: 159 KB
Volume: 20
Category: Article
ISSN: 0937-3462
DOI: 10.1007/s00192-009-0969-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-daily trospium chloride 60 mg exten

Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms

✍ Norman R. Zinner; Roger R. Dmochowski; David R. Staskin; Paul F. Siami; Peter K. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

Obesity is associated with a more severe

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release

✍ Michael B. Chancellor; Michael G. Oefelein; Sandip Vasavada 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

## Abstract ## Aims Obesity is an established risk factor for urinary incontinence, yet no information exists as to the efficacy of antimuscarinic agents in this population. The goal of this study is to examine the efficacy of once daily trospium chloride (Sanctura™) XR in overweight and obese pat

Effectiveness and tolerability of extend

Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder

✍ Rodney U. Anderson; Scott MacDiarmid; Sherron Kell; James H. Barada; Scott Serel 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 137 KB

A new once-daily formulation of tolterod

A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder

✍ S. Swift; A. Garely; T. Dimpfl; C. Payne; on behalf of the Tolterodine Study Gro 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 91 KB